Attached files

file filename
EX-23.1 - CONSENT OF MARCUM LLP - Gene Biotherapeutics, Inc.dex231.htm
10-K - FORM 10-K - Gene Biotherapeutics, Inc.d10k.htm
EX-21 - SUBSIDIARIES OF THE REGISTRANT - Gene Biotherapeutics, Inc.dex21.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - Gene Biotherapeutics, Inc.dex311.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - Gene Biotherapeutics, Inc.dex312.htm

Exhibit 32

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Cardium Therapeutics, Inc., a Delaware corporation, does hereby certify, to such officer’s knowledge, that the Annual Report on Form 10-K for the fiscal year ended December 31, 2010 of Cardium Therapeutics, Inc. fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Cardium Therapeutics, Inc.

 

Date: April 15, 2011   

/s/ Christopher J. Reinhard

   Christopher J. Reinhard, Chief Executive Officer
Date: April 15, 2011   

/s/ Dennis M. Mulroy

   Dennis M. Mulroy, Chief Financial Officer

The foregoing certification is furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-K or as a separate disclosure document.